Mouse Anti-DHRS9 Recombinant Antibody (CBYCD-266) (V2LY-0425-LY284)

Belyaeva, O. V., Wirth, S. E., Boeglin, W. E., Karki, S., Goggans, K. R., Wendell, S. G., ... & Kedishvili, N. Y. (2022). Dehydrogenase reductase 9 (SDR9C4) and related homologs recognize a broad spectrum of lipid mediator oxylipins as substrates. Journal of Biological Chemistry, 298(1).

Li, H. B., Zhou, J., Zhao, F., Yu, J., & Xu, L. (2020). Prognostic impact of DHRS9 overexpression in pancreatic cancer. Cancer Management and Research, 12, 5997.

Shimomura, H., Sasahira, T., Nakashima, C., Shimomura-Kurihara, M., & Kirita, T. (2018). Downregulation of DHRS9 is associated with poor prognosis in oral squamous cell carcinoma. Pathology, 50(6), 642-647.

Bitterer, F., Amodio, G., Macedo, C., Moreau, A., Obermajer, N., Fraendrich, F., ... & Riquelme, P. (2018). DHRS9 is a Stable Marker of Human Regulatory Macrophages. Transplantation, 102, S18-S19.

Riquelme, P., Amodio, G., Macedo, C., Moreau, A., Obermajer, N., Brochhausen, C., ... & Hutchinson, J. A. (2017). DHRS9 is a stable marker of human regulatory macrophages. Transplantation, 101(11), 2731.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols